Get the Stockscreener App
0.00
100.00%
-3.65
Revance Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
See More
Previous Close:
$3.65
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$378.94M
Revenue:
$234.04M
Net Income/Loss:
$-323.92M
P/E Ratio:
0.00
EPS:
-3.8
Net Cash Flow:
$-223.46M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$6.65
Revance Therapeutics Inc Stock (RVNC) Company Profile
Name
Revance Therapeutics Inc
Sector
Industry
Phone
(615) 724-7755
Address
1222 DEMONBREUN STREET, NASHVILLE, CA
Compare RVNC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVNC
Revance Therapeutics Inc
|
0.00 | 378.94M | 234.04M | -323.92M | -223.46M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Downgrade | Mizuho | Buy → Neutral |
| Jan-09-24 | Downgrade | Goldman | Buy → Neutral |
| Aug-16-23 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-22-22 | Initiated | Goldman | Buy |
| Oct-25-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-15-20 | Reiterated | Needham | Buy |
| Aug-11-20 | Resumed | Mizuho | Buy |
| Mar-23-20 | Downgrade | Goldman | Buy → Neutral |
| Dec-02-19 | Initiated | Goldman | Buy |
| Oct-30-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Feb-15-19 | Initiated | Wells Fargo | Market Perform |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
| Nov-16-18 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-17-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Apr-20-18 | Reiterated | Mizuho | Buy |
| Mar-27-18 | Initiated | Needham | Buy |
| Mar-05-18 | Initiated | Goldman | Buy |
| Jan-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-06-17 | Initiated | Guggenheim | Buy |
| Dec-06-17 | Reiterated | Mizuho | Buy |
| Nov-27-17 | Initiated | Barclays | Overweight |
| Nov-17-17 | Initiated | Mizuho | Buy |
| Aug-22-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Revance Therapeutics Inc Stock (RVNC) Latest News
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Two Sigma Investments LP Acquires 13,539 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Ameriprise Financial Inc. Raises Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Investor Network: Revance Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
BNP Paribas Financial Markets Sells 10,728 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Deutsche Bank AG Grows Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Jane Street Group LLC Sells 491,504 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
ProShare Advisors LLC Increases Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Rating of “Hold” by Brokerages - Defense World
Millennium Management LLC Increases Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Announces Blue Lizard® Australian Sunscreen Times Square Takeover to Celebrate National Sunscreen Day - The Malaysian Reserve
The Gross Law Firm Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – RVNC - Louisiana First News
Northern Trust Corp Has $3.01 Million Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at Wall Street Zen - Defense World
Revance Names New CEO to Drive Next Phase in Aesthetic Innovation - Global Cosmetics News
Revance Announces Blue Lizard Australian Sunscreen® Partnership with The Bentway for Their Summer 2025 Sun/Shade Program - The Malaysian Reserve
Revance Announces Leadership Succession Plan to Support Next Phase of Growth and Innovation - Longview News-Journal
Price T Rowe Associates Inc. MD Purchases 7,839 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - ACCESS Newswire
Dermata Therapeutics, Inc. SEC 10-Q Report - TradingView
Revolutionary Once-Weekly Natural Acne Treatment Achieves Breakthrough in Phase 3 Trial Results - Stock Titan
Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com - Defense World
Hsbc Holdings PLC Cuts Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Revance Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Acquired by Wells Fargo & Company MN - Defense World
Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC - ACCESS Newswire
MetLife Investment Management LLC Has $184,000 Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) PT at $8.39 - Defense World
Invesco Ltd. Boosts Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com - Defense World
Spasticity Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Jazz Pharmaceuticals, Revance Therapeutics, Ipsen - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by LPL Financial LLC - Defense World
Revance Announces Blue Lizard® Australian Sunscreen Named the #1 Selling Mineral Sunscreen Brand - StreetInsider
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com - Defense World
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineRVNC - ACCESS Newswire
Geode Capital Management LLC Raises Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Investigation announced for Long-Term Investors in Revance - openPR.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
Revance Therapeutics Inc Stock (RVNC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):